Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Novartis AG
Novartis AG News
Novartis AG Quantitative Score
About Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Novartis AG Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Novartis AG Financials
Table Compare
Compare NVS metrics with: | |||
|---|---|---|---|
Earnings & Growth | NVS | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | NVS | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | NVS | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | NVS | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Novartis AG Income
Novartis AG Balance Sheet
Novartis AG Cash Flow
Novartis AG Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Buy |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Novartis AG Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 14.5976 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| 2025-04-25 | 3.994 | Quarterly |
| 2024-04-19 | 3.7772 | Quarterly |
| 2023-03-20 | 3.46936 | Quarterly |
| 2022-03-17 | 3.357 | Quarterly |
| 2021-03-15 | 3.378 | Quarterly |
Historical Market Cap
Shares Outstanding
Novartis AG Executives
| Name | Role |
|---|---|
| Dr. Vasant Narasimhan M.D. | Chief Executive Officer |
| Mr. Victor Bulto | President of US |
| Dr. Patrick Horber M.D. | President of International |
| Mr. Harry Kirsch | Chief Financial Officer |
| Ms. Karen L. Hale | Chief Legal & Compliance Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Vasant Narasimhan M.D. | Chief Executive Officer | 1976 | 8.01M | |
| Mr. Victor Bulto | President of US | Male | 1978 | 4.27M |
| Dr. Patrick Horber M.D. | President of International | 1970 | 4.06M | |
| Mr. Harry Kirsch | Chief Financial Officer | Male | 1965 | 3.97M |
| Ms. Karen L. Hale | Chief Legal & Compliance Officer | Female | 1968 | 2.56M |